Following these key PD-1/PD-L1 data, studies in patients with cutaneous melanoma and OSA observed that plasma-soluble PD-L1 (sPD-L1) correlated with melanoma aggressiveness based on the Breslow index, in both advanced primary tumor stages and patients with locoregional disease. This evidence concerns the gene CD274 and melanoma.